Читать книгу The Esophagus - Группа авторов - Страница 32
References
Оглавление1 1 Modlin IM, Moss SF, Kidd M, Lye KD. Gastroesophageal reflux disease: then and now. J Clin Gastroenterol 2004; 38(5):390–402.
2 2 Enterline HT, Pathology of the esophagus. Springer‐Verlag; 1984.
3 3 Paterson W. Esophageal peristalsis. GI Motility Online. 2006. https://www.nature.com/gimo/contents/pt1/full/gimo13.html.
4 4 Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med 2008; 359(16):1700–1707.
5 5 Sengupta JN. An overview of esophageal sensory receptors. Am J Med 2000; 108(87S–89S).
6 6 Sleisenger M, Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology, diagnosis, and management. 9th ed. Saunders/Elsevier; 2010.
7 7 Knowles CH, Aziz Q. Visceral hypersensitivity in non‐erosive reflux disease. Gut. 2008; 57(5):674–683.
8 8 Orlando RC. Esophageal perception and noncardiac chest pain. Gastroenterol Clin North Am 2004; 33(1):25–33.
9 9 Sengupta JN. Esophageal sensory physiology. GI Motility Online. 2006. https://www.nature.com/gimo/contents/pt1/full/gimo16.html.
10 10 Eslick GD, Talley NJ. Dysphagia: epidemiology, risk factors and impact on quality of life – a population‐based study. Aliment Pharmacol Ther 2008; 27(10):971–979.
11 11 Cho SY, Choung RS, Saito YA, Schleck CD, Zinsmeister AR, Locke GR, 3rd, et al. Prevalence and risk factors for dysphagia: a USA community study. Neurogastroenterol Motil 2015; 27(2):212–219.
12 12 Sperry SL, Woosley JT, Shaheen NJ, Dellon ES. Influence of race and gender on the presentation of eosinophilic esophagitis. Am J Gastroenterol 2012; 107(2):215–221.
13 13 Ahmed M. Eosinophilic esophagitis in adults: An update. World J Gastrointest Pharmacol Ther 2016; 7(2):207–213.
14 14 Cook IJ, Kahrilas PJ. AGA technical review on management of oropharyngeal dysphagia. Gastroenterology. 1999; 116(2):455–478.
15 15 Wilcox CM, Alexander LN, Clark WS. Localization of an obstructing esophageal lesion. Is the patient accurate? Dig Dis Sci 1995; 40(10):2192–2196.
16 16 Spieker MR. Evaluating dysphagia. Am Fam Physician 2000; 61(12):3639–36348.
17 17 Abid S, Mumtaz K, Jafri W, Hamid S, Abbas Z, Shah HA, et al. Pill‐induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy. 2005; 37(8):740–744.
18 18 Abdel Jalil AA, Katzka DA, Castell DO. Approach to the patient with dysphagia. Am J Med 2015; 128(10):1138.e17–e23.
19 19 Levine MS, Rubesin SE, Laufer I. Barium esophagography: a study for all seasons. Clin Gastroenterol Hepatol 2008; 6(1):11–25.
20 20 Spechler SJ. AGA technical review on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology. 1999; 117(1):233–254.
21 21 Ott DJ, Gelfand DW, Lane TG, Wu WC. Radiologic detection and spectrum of appearances of peptic esophageal strictures. J Clin Gastroenterol 1982; 4(1):11–15.
22 22 Ott DJ, Chen YM, Wu WC, Gelfand DW, Munitz HA. Radiographic and endoscopic sensitivity in detecting lower esophageal mucosal ring. AJR Am J Roentgenol 1986; 147(2):261–265.
23 23 Gallo SH, McClave SA, Makk LJ, Looney SW. Standardization of clinical criteria required for use of the 12.5 millimeter barium tablet in evaluating esophageal lumenal patency. Gastrointest Endosc 1996; 44(2):181–184.
24 24 Richter JE. How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol 2007; 4(12):658–664.
25 25 Sutton FM, Graham DY, Goodgame RW. Infectious esophagitis. Gastrointest Endosc Clin N Am 1994;4( 4):713–729.
26 26 Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence‐based consensus. Am J Gastroenterol 2006; 101(8):1900–1920; quiz 43.
27 27 Dent J, Vakil N, Jones R, Bytzer P, Schoning U, Halling K, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut. 2010; 59(6):714–721.
28 28 Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional esophageal disorders. Gastroenterology. 2016; 150:1368–1379.
29 29 Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016; 150(6):1380–1392.
30 30 Ford AC, Suares NC, Talley NJ. Meta‐analysis: the epidemiology of noncardiac chest pain in the community. Aliment Pharmacol Ther 2011; 34(2):172–180.
31 31 Eslick GD, Fass R. Noncardiac chest pain: evaluation and treatment. Gastroenterol Clin North Am 2003; 32(2):531–552.
32 32 Hewson EG, Sinclair JW, Dalton CB, Richter JE. Twenty‐four‐hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain. Am J Med 1991; 90(5):576–583.
33 33 DeMeester TR, O’Sullivan GC, Bermudez G, Midell AI, Cimochowski GE, O’Drobinak J. Esophageal function in patients with angina‐type chest pain and normal coronary angiograms. Ann Surg 1982; 196(4):488–498.
34 34 Galmiche JP, Clouse RE, Balint A, Cook IJ, Kahrilas PJ, Paterson WG, et al. Functional esophageal disorders. Gastroenterology. 2006; 130(5):1459–1465.
35 35 Moloy PJ, Charter R. The globus symptom. Incidence, therapeutic response, and age and sex relationships. Ann Surg 1982; 108(11):740–744.
36 36 Wilson JA, Heading RC, Maran AG, Pryde A, Piris J, Allan PL. Globus sensation is not due to gastro‐oesophageal reflux. Clin Otolaryngol Allied Sci 1987; 12(4):271–275.
37 37 Bajbouj M, Becker V, Eckel F, Miehlke S, Pech O, Prinz C, et al. Argon plasma coagulation of cervical heterotopic gastric mucosa as an alternative treatment for globus sensations. Gastroenterology. 2009; 137(2):440–444.
38 38 Kristo I, Rieder E, Paireder M, Schwameis K, Jomrich G, Dolak W, et al. Radiofrequency ablation in patients with large cervical heterotopic gastric mucosa and globus sensation: Closing the treatment gap. Dig Endosc 2018; 30(2):212–218.
39 39 Thompson WG, Heaton KW. Heartburn and globus in apparently healthy people. Can Med Assoc J 1982; 126(1):46–48.
40 40 Brown SR, Schwartz JM, Summergrad P, Jenike MA. Globus hystericus syndrome responsive to antidepressants. Am J Psychiatry 1986; 143(7):917–918.
41 41 Kiebles JL, Kwiatek MA, Pandolfino JE, Kahrilas PJ, Keefer L. Do patients with globus sensation respond to hypnotically assisted relaxation therapy? A case series report. Dis Esophagus 2010; 23(7):545–553.
42 42 You LQ, Liu J, Jia L, Jiang SM, Wang GQ. Effect of low‐dose amitriptyline on globus pharyngeus and its side effects. World J Gastroenterol 2013; 19(42):7455–7460.
43 43 Kirch S, Gegg R, Johns MM, Rubin AD. Globus pharyngeus: effectiveness of treatment with proton pump inhibitors and gabapentin. Ann Otol Rhinol Laryngol 2013; 122(8):492–495.
44 44 Havemann BD, Henderson CA, El‐Serag HB. The association between gastro‐oesophageal reflux disease and asthma: a systematic review. Gut. 2007; 56(12):1654–1664.
45 45 Blakey JD, Price DB, Pizzichini E, Popov TA, Dimitrov BD, Postma DS, et al. Identifying risk of future asthma attacks using UK medical record data: a respiratory effectiveness group initiative. J Allergy Clin Immunol Pract 2017; 5(4):1015–1024.e8.
46 46 Chipps BE, Haselkorn T, Paknis B, Ortiz B, Bleecker ER, Kianifard F, et al. More than a decade follow‐up in patients with severe or difficult‐to‐treat asthma: the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) II. J Allergy Clin Immunol 2018; 141(5):1590–1597.e9.
47 47 Almario CV, Ballal ML, Chey WD, Nordstrom C, Khanna D, Spiegel BMR. Burden of gastrointestinal symptoms in the United States: results of a nationally representative survey of over 71,000 Americans. Am J Gastroenterol 2018; 113(11):1701–1710.
48 48 Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019; 156(1):254–272.e11.
49 49 Wahlqvist P, Brook RA, Campbell SM, Wallander MA, Alexander AM, Smeeding JE, et al. Objective measurement of work absence and on‐the‐job productivity: a case‐control study of US employees with and without gastroesophageal reflux disease. J Occup Environ Med 2008; 50(1):25–31.
50 50 Henke CJ, Levin TR, Henning JM, Potter LP. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000; 95(3):788–792.
51 51 Brook RA, Wahlqvist P, Kleinman NL, Wallander MA, Campbell SM, Smeeding JE. Cost of gastro‐oesophageal reflux disease to the employer: a perspective from the United States. Aliment Pharmacol Ther 2007; 26(6):889–898.
52 52 Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002; 122(5):1500–1511.
53 53 Leodolter A, Nocon M, Kulig M, Willich SN, Malfertheiner P, Labenz J. Gastro esophageal reflux disease is associated with absence from work: results from a prospective cohort study. World J Gastroenterol 2005; 11(45):7148–7151.
54 54 Gross M, Beckenbauer U, Burkowitz J, Walther H, Brueggenjuergen B. Impact of gastro‐oesophageal reflux disease on work productivity despite therapy with proton pump inhibitors in Germany. Eur J Med Res 2010; 15(3):124–130.
55 55 McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36‐item short‐form health survey (SF‐36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31(3):247–263.
56 56 Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health‐related quality of life. Am J Med 1998; 104(3):252–258.
57 57 Fass R. Symptom assessment tools for gastroesophageal reflux disease (GERD) treatment. J Clin Gastroenterol 2007; 41(5):437–444.
58 58 Shikiar R, Flood E, Siddique R, Howell J, Dodd SL. Development and validation of the gastroesophageal reflux disease treatment satisfaction questionnaire. Dig Dis Sci 2005; 50(11):2025–2033.
59 59 Velanovich V. The development of the GERD‐HRQL symptom severity instrument. Dis Esophagus 2007; 20(2):130–134.
60 60 Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94(7):1782–1789.
61 61 Pace F, Negrini C, Wiklund I, Rossi C, Savarino V. Quality of life in acute and maintenance treatment of non‐erosive and mild erosive gastro‐oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22(4):349–356.
62 62 Kovacs TO, Freston JW, Haber MM, Atkinson S, Hunt B, Peura DA. Long‐term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole. Dig Dis Sci 2010; 55(5):1325–1336.
63 63 Damiano A, Siddique R, Xu X, Johanson J, Sloan S. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci 2003; 48(4):657–662.
64 64 de Souza Cury M, Ferrari AP, Ciconelli R, Ferraz MB, Moraes‐Filho JP. Evaluation of health‐related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole. Dis Esophagus 2006; 19(4):289–293.
65 65 Slim K, Bousquet J, Kwiatkowski F, Lescure G, Pezet D, Chipponi J. Quality of life before and after laparoscopic fundoplication. Am J Surg 2000; 180(1):41–45.
66 66 Velanovich V, Vallance SR, Gusz JR, Tapia FV, Harkabus MA. Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg 1996; 183(3):217–224.
67 67 Mathias SD, Colwell HH, Miller DP, Pasta DJ, Henning JM, Ofman JJ. Health‐Related quality‐of‐life and quality‐days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine. Dig Dis Sci 2001; 46(11):2416–2423.
68 68 Pare P, Armstrong D, Pericak D, Pyzyk M. Pantoprazole rapidly improves health‐related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. J Clin Gastroenterol 2003; 37(2):132–138.
69 69 Grudell AB, Alexander JA, Enders FB, Pacifico R, Fredericksen M, Wise JL, et al. Validation of the Mayo Dysphagia Questionnaire. Dis Esophagus 2007; 20(3):202–205.
70 70 McHorney CA, Robbins J, Lomax K, Rosenbek JC, Chignell K, Kramer AE, et al. The SWAL‐QOL and SWAL‐CARE outcomes tool for oropharyngeal dysphagia in adults: III. Documentation of reliability and validity. Dysphagia. 2002; 17(2):97–114.
71 71 Chen AY, Frankowski R, Bishop‐Leone J, Hebert T, Leyk S, Lewin J, et al. The development and validation of a dysphagia‐specific quality‐of‐life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Sur 2001; 127(7):870–876.
72 72 Schoepfer AM, Straumann A, Panczak R, Coslovsky M, Kuehni CE, Maurer E, et al. Development and validation of a symptom‐based activity index for adults with eosinophilic esophagitis. Gastroenterology. 2014; 147(6):1255–1266.e21.
73 73 Franciosi JP, Hommel KA, Greenberg AB, DeBrosse CW, Greenler AJ, Abonia JP, et al. Development of the pediatric quality of life inventory eosinophilic esophagitis module items: qualitative methods. BMC Gastroenterol 2012; 12:135.
74 74 Ross D, Richter J, Velanovich V. Health‐related quality of life and physiological measurements in achalasia. Dis Esophagus 2017; 30(2):1–5.
75 75 Urbach DR, Tomlinson GA, Harnish JL, Martino R, Diamant NE. A measure of disease‐specific health‐related quality of life for achalasia. Am J Gastroenterol 2005; 100(8):1668–1676.
76 76 Taft TH, Carlson DA, Triggs J, Craft J, Starkey K, Yadlapati R, et al. Evaluating the reliability and construct validity of the Eckardt symptom score as a measure of achalasia severity. Neurogastroenterol Motil. 2018; 30(6):e13287.
77 77 Slone SO, Richter JE, Velanovich V, Jacobs JW, Kumar A. Achalasia quality of life score and eckardt score: a comparison for the assessment of clinical improvement post treatment for achalasia. Accepted by Dis Esophagus (in press).
78 78 Youssef Y, Richards WO, Sharp K, Holzman M, Sekhar N, Kaiser J, et al. Relief of dysphagia after laparoscopic Heller myotomy improves long‐term quality of life. J Gastrointest Surg 2007; 11(3):309–313.
79 79 Dang Y, Mercer D. Treatment of esophageal achalasia with Heller myotomy: retrospective evaluation of patient satisfaction and disease‐specific quality of life. Can J Surg 2006; 49(4):267–271.
80 80 Chrystoja CC, Darling GE, Diamant NE, Kortan PP, Tomlinson GA, Deitel W, et al. Achalasia‐specific quality of life after pneumatic dilation or laparoscopic Heller myotomy with partial fundoplication: a multicenter, randomized clinical trial. Am J Gastroenterol 2016; 111(11):1536–1545.
81 81 Chan SM, Chiu PW, Wu JC, Kwan SM, Kwong PY, Lam KW, et al. Laparoscopic Heller’s cardiomyotomy achieved lesser recurrent dysphagia with better quality of life when compared with endoscopic balloon dilatation for treatment of achalasia. Dis Esophagus 2013; 26(3):231–236.
82 82 Katilius M, Velanovich V. Heller myotomy for achalasia: quality of life comparison of laparoscopic and open approaches. JSLS 2001; 5(3):227–231.
83 83 Allen CJ, Parameswaran K, Belda J, Anvari M. Reproducibility, validity, and responsiveness of a disease‐specific symptom questionnaire for gastroesophageal reflux disease. Dis Esophagus 2000; 13(4):265–270.
84 84 Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28(8):681–687.
85 85 Rothman M, Farup C, Stewart W, Helbers L, Zeldis J. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci 2001; 46(7):1540–1549.
86 86 Williford WO, Krol WF, Spechler SJ. Development for and results of the use of a gastroesophageal reflux disease activity index as an outcome variable in a clinical trial. VA cooperative study group on gastroesophageal reflux disease (GERD). Control Clin Trials 1994; 15(5):335–348.
87 87 Pare P, Meyer F, Armstrong D, Pyzyk M, Pericak D, Goeree R. Validation of the GSFQ, a self‐administered symptom frequency questionnaire for patients with gastroesophageal reflux disease. Can J Gastroenterol 2003; 17(5):307–312.
88 88 Liu JY, Woloshin S, Laycock WS, Rothstein RI, Finlayson SR, Schwartz LM. Symptoms and treatment burden of gastroesophageal reflux disease: validating the GERD assessment scales. Arch Intern Med 2004; 164(18):2058–2064.
89 89 Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7(1):75–83.
90 90 Svedlund J, Sjodin I, Dotevall G. GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33(2):129–134.
91 91 Rentz AM, Kahrilas P, Stanghellini V, Tack J, Talley NJ, de la Loge C, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI‐SYM) in patients with upper gastrointestinal disorders. Qual Life Res 2004; 13(10):1737–1749.
92 92 Nocon M, Kulig M, Leodolter A, Malfertheiner P, Willich SN. Validation of the Reflux Disease Questionnaire for a German population. Eur J Gastroenterol Hepatol 2005; 17(2):229–233.
93 93 Wong WM, Lam KF, Lai KC, Hui WM, Hu WH, Lam CL, et al. A validated symptoms questionnaire (Chinese GERDQ) for the diagnosis of gastro‐oesophageal reflux disease in the Chinese population. Aliment Pharmacol Ther 2003; 17(11):1407–1413.
94 94 Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 2004; 39(9):888–891.
95 95 Armstrong D, Veldhuyzen SJ, Chung SA, Shapiro CM, Dhillon S, Escobedo S, et al. Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test. Can J Gastroenterol 2005; 19(6):350–358.
96 96 Puhan MA, Guyatt GH, Armstrong D, Wiklund I, Fallone CA, Heels‐Ansdell D, et al. Validation of a symptom diary for patients with gastro‐oesophageal reflux disease. Aliment Pharmacol Ther 2006; 23(4):531–541.
97 97 Armstrong D, Monnikes H, Bardhan KD, Stanghellini V. The construction of a new evaluative GERD questionnaire – methods and state of the art. Digestion. 2007; 75 Suppl 1:17–24.
98 98 Bardhan KD, Stanghellini V, Armstrong D, Berghöfer P, Gatz G, Mönnikes H. International validation of ReQuest™ in patients with endoscopy‐negative gastro‐oesophageal reflux disease. Digestion. 2007; 75(suppl 1):48–54.
99 99 Monnikes H, Bardhan KD, Stanghellini V, Berghofer P, Bethke TD, Armstrong D. Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion. 2007; 75 Suppl 1:41–47.
